Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades

Neuropharmacology

Volumn 62, Issue 7, 2012, Pages 2184-2191

  Delille, Hannah K ^a   Becker, Judith M ^a   Burkhardt, Sabrina ^a   Bleher, Barbara ^a   Terstappen, Georg C ^a   Schmidt, Martin ^a   Meyer, Axel H ^a   Unger, Liliane ^a   Marek, Gerard J ^b   Mezler, Mario ^a  

^a ABBOTT GMBH AND CO KG   (Germany)

^b ABBOTT LABORATORIES   (United States)

Author keywords

GPCR crosstalk; Heterocomplex

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; CYCLIC AMP; EGLUMETAD; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR;

ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; HUMAN; HUMAN CELL; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; SECOND MESSENGER; SIGNAL TRANSDUCTION;

EID: 84859099981     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.01.010     Document Type: Article

References (44)

1. G.K. Aghajanian, and G.J. Marek Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release Brain Res. 825 1999 161 171 (Pubitemid 29222872)
2. L. Albizu, T. Holloway, J. Gonzalez-Maeso, and S.C. Sealfon Functional crosstalk and heteromerization of serotonin 5-HT(2A) and dopamine D(2) receptors Neuropharmacology 61 2011 770 777
3. M.A. Benneyworth, Z. Xiang, R.L. Smith, E.E. Garcia, P.J. Conn, and E. Sanders-Bush A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis Mol. Pharmacol. 72 2007 477 484 (Pubitemid 47124127)
4. C. Brock, N. Oueslati, S. Soler, L. Boudier, P. Rondard, and J.P. Pin Activation of a dimeric metabotropic glutamate receptor by intersubunit rearrangement J. Biol. Chem. 282 2007 33000 33008 (Pubitemid 350161742)
5. M. Canals, and G. Milligan Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors J. Biol. Chem. 283 2008 11424 11434
6. A. Carlsson Antipsychotic drugs, neurotransmitters, and schizophrenia Am. J. Psychiatry 135 1978 165 173
7. P.J. Conn, and J.P. Pin Pharmacology and functions of metabotropic glutamate receptors Annu. Rev. Pharmacol. Toxicol. 37 1997 205 237 (Pubitemid 27238875)
8. D. Cussac, E. Boutet-Robinet, M.C. Ailhaud, A. Newman-Tancredi, J.C. Martel, N. Danty, and I. Rauly-Lestienne Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells Eur. J. Pharmacol. 594 2008 32 38
9. E. Doumazane, P. Scholler, J.M. Zwier, E. Trinquet, P. Rondard, and J.P. Pin A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors FASEB J. 2010
10. H.A. Feldman Mathematical theory of complex ligand-binding systems of equilibrium: some methods for parameter fitting Anal. Biochem. 48 1972 317 338
11. S. Ferre, R. Baler, M. Bouvier, M.G. Caron, L.A. Devi, T. Durroux, K. Fuxe, S.R. George, J.A. Javitch, M.J. Lohse, K. Mackie, G. Milligan, K.D. Pfleger, J.P. Pin, N.D. Volkow, M. Waldhoer, A.S. Woods, and R. Franco Building a new conceptual framework for receptor heteromers Nat. Chem. Biol. 5 2009 131 134
12. R. Freedman Schizophrenia N. Engl. J. Med. 349 2003 1738 1749 (Pubitemid 37315012)
13. M. Fribourg, J.L. Moreno, T. Holloway, D. Provasi, L. Baki, R. Mahajan, G. Park, S.K. Adney, C. Hatcher, J.M. Eltit, J.D. Ruta, L. Albizu, Z. Li, A. Umali, J. Shim, A. Fabiato, A.D. Mackerell Jr., V. Brezina, S.C. Sealfon, M. Filizola, J. Gonzalez-Maeso, and D.E. Logothetis Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs Cell 147 2011 1011 1023
14. J.C. Gewirtz, and G.J. Marek Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors Neuropsychopharmacology 23 2000 569 576
15. M.A. Geyer, and F.X. Vollenweider Serotonin research: contributions to understanding psychoses Trends Pharmacol. Sci. 29 2008 445 453
16. J. Gonzalez-Maeso, R.L. Ang, T. Yuen, P. Chan, N.V. Weisstaub, J.F. Lopez-Gimenez, M. Zhou, Y. Okawa, L.F. Callado, G. Milligan, J.A. Gingrich, M. Filizola, J.J. Meana, and S.C. Sealfon Identification of a serotonin/glutamate receptor complex implicated in psychosis Nature 452 2008 93 97 (Pubitemid 351355090)
17. J. Gonzalez-Maeso, N.V. Weisstaub, M. Zhou, P. Chan, L. Ivic, R. Ang, A. Lira, M. Bradley-Moore, Y. Ge, Q. Zhou, S.C. Sealfon, and J.A. Gingrich Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior Neuron 53 2007 439 452 (Pubitemid 46161267)
18. J. Gonzalez-Maeso, T. Yuen, B.J. Ebersole, E. Wurmbach, A. Lira, M. Zhou, N. Weisstaub, R. Hen, J.A. Gingrich, and S.C. Sealfon Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex J. Neurosci. 23 2003 8836 8843 (Pubitemid 37210895)
19. Kinon, B.J., Adams, D.H., Baygani, S., Millen, B., Velona, I., Kollack-Walker, S., 2011. A long-term, phase 2, safety study of LY2140023 monohydrate versus atypical antipsychotic standard of care in Schizophrenia. In: 13th International Congress on Schizophrenia Research, Colorado Springs, CO, USA.
20. G.J. Marek, R.A. Wright, J.C. Gewirtz, and D.D. Schoepp A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex Neuroscience 105 2001 379 392 (Pubitemid 32728122)
21. G.J. Marek, R.A. Wright, D.D. Schoepp, J.A. Monn, and G.K. Aghajanian Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex J. Pharmacol. Exp. Ther. 292 2000 76 87 (Pubitemid 30026356)
22. G.J. Marek, and C. Zhang Activation of metabotropic glutamate 5 (mGlu5) receptors induces spontaneous excitatory synaptic currents in layer V pyramidal cells of the rat prefrontal cortex Neurosci. Lett. 442 2008 239 243
23. D. Maurel, L. Comps-Agrar, C. Brock, M.L. Rives, E. Bourrier, M.A. Ayoub, H. Bazin, N. Tinel, T. Durroux, L. Prezeau, E. Trinquet, and J.P. Pin Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization Nat. Methods 5 2008 561 567 (Pubitemid 351761765)
24. L.T. Meltzer, J.N. Wiley, and T.G. Heffner The alpha 2-adrenoceptor antagonists idazoxan and yohimbine can unmask the postsynaptic dopamine agonist effects of B-HT 920 Eur. J. Pharmacol. 170 1989 105 107 (Pubitemid 19263230)
25. M. Mezler, H. Geneste, L. Gault, and G.J. Marek LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr.Opin.Investig Drugs 11 2010 833 845
26. B. Moghaddam, and B.W. Adams Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats Science 281 1998 1349 1352 (Pubitemid 28406826)
27. G. Molinaro, A. Traficante, B. Riozzi, L. Di Menna, M. Curto, S. Pallottino, F. Nicoletti, V. Bruno, and G. Battaglia Activation of mGlu2/3 metabotropic glutamate receptors negatively regulates the stimulation of inositol phospholipid hydrolysis mediated by 5-hydroxytryptamine2A serotonin receptors in the frontal cortex of living mice Mol. Pharmacol. 76 2009 379 387
28. J.L. Moreno, T. Holloway, L. Albizu, S.C. Sealfon, and J. Gonzalez-Maeso Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists Neurosci. Lett. 493 2011 76 79
29. P.J. Munson, and D. Rodbard Ligand: a versatile computerized approach for characterization of ligand-binding systems Anal. Biochem. 107 1980 220 239
30. S.T. Patil, L. Zhang, F. Martenyi, S.L. Lowe, K.A. Jackson, B.V. Andreev, A.S. Avedisova, L.M. Bardenstein, I.Y. Gurovich, M.A. Morozova, S.N. Mosolov, N.G. Neznanov, A.M. Reznik, A.B. Smulevich, V.A. Tochilov, B.G. Johnson, J.A. Monn, and D.D. Schoepp Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial Nat. Med. 13 2007 1102 1107 (Pubitemid 47517511)
31. J.P. Pin, R. Neubig, M. Bouvier, L. Devi, M. Filizola, J.A. Javitch, M.J. Lohse, G. Milligan, K. Palczewski, M. Parmentier, and M. Spedding International union of basic and clinical pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers Pharmacol. Rev. 59 2007 5 13 (Pubitemid 46335687)
32. L. Prezeau, M.L. Rives, L. Comps-Agrar, D. Maurel, J. Kniazeff, and J.P. Pin Functional crosstalk between GPCRs: with or without oligomerization Curr. Opin. Pharmacol. 10 2010 6 13
33. M.L. Rives, C. Vol, Y. Fukazawa, N. Tinel, E. Trinquet, M.A. Ayoub, R. Shigemoto, J.P. Pin, and L. Prezeau Crosstalk between GABAB and mGlu1a receptors reveals new insight into GPCR signal integration EMBO J. 28 2009 2195 2208
34. A. Sawa, and S.H. Snyder Schizophrenia: neural mechanisms for novel therapies Mol. Med. 9 2003 3 9 (Pubitemid 36667686)
35. C.L. Schmid, and L.M. Bohn Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ss-arrestin2/Src/Akt signaling complex in vivo J. Neurosci. 30 2010 13513 13524
36. R. Schreiber, M. Brocco, and M.J. Millan Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone Eur. J. Pharmacol. 264 1994 99 102 (Pubitemid 24310841)
37. P.R. Selvin Principles and biophysical applications of lanthanide-based probes Annu. Rev. Biophys. Biomol. Struct. 31 2002 275 302 (Pubitemid 34666834)
38. W.P. Spooren, F. Gasparini, P.H. van der, M. Koller, S. Nakanishi, and R. Kuhn Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice Eur. J. Pharmacol. 397 2000 R1 R2
39. Stauffer, V.L., Ayan-Oshodi, M.A., Wondmagegnehu, E.T., Wrishko, R.E., Kryzhanovskaya, L., Anderson, S., 2011. A study investigating the potential interaction between LY2140023 and antipsychotic treatments in subjects with schizophrenia or schizoaffective disorder. 51st Anniversary Meeting of New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, USA.
40. P.S. Talbot, and M. Laruelle The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development Eur. Neuropsychopharmacol. 12 2002 503 511 (Pubitemid 35408701)
41. C.A. Tamminga, and H.H. Holcomb Phenotype of schizophrenia: a review and formulation Mol. Psychiatry 10 2005 27 39 (Pubitemid 40139587)
42. F.X. Vollenweider, M.F. Vollenweider-Scherpenhuyzen, A. Babler, H. Vogel, and D. Hell Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action Neuroreport 9 1998 3897 3902 (Pubitemid 29189323)
43. M.L. Woolley, D.J. Pemberton, S. Bate, C. Corti, and D.N. Jones The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity Psychopharmacology (Berl) 196 2008 431 440
44. R.A. Wright, M.B. Arnold, W.J. Wheeler, P.L. Ornstein, and D.D. Schoepp [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain J. Pharmacol. Exp. Ther. 298 2001 453 460 (Pubitemid 32673394)